Verve Therapeutics Inc (NASDAQ:VERV) price on Wednesday, April 30, rose 3.85% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.67.
A look at the stock’s price movement, the close in the last trading session was $5.46, moving within a range at $5.304 and $5.745. The beta value (5-Year monthly) was 1.867. Turning to its 52-week performance, $9.31 and $2.86 were the 52-week high and 52-week low respectively. Overall, VERV moved 24.07% over the past month.
Verve Therapeutics Inc’s market cap currently stands at around $505.44 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests up to a 64.63% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 24.18M, representing a -25.21% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VERV is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend VERV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VERV’s current price about 26.71% and 3.81% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 58.03, while 7-day volatility ratio is 7.63% and 13.32% in the 30-day chart. Further, Verve Therapeutics Inc (VERV) has a beta value of 1.83, and an average true range (ATR) of 0.58. Analysts have given the company’s stock an average 52-week price target of $14.5, forecast between a low of $14 and high of $15. Looking at the price targets, the low is -146.91% off current price level while to achieve the yearly target high, price needs to move -164.55%. Nonetheless, investors will most likely welcome a -155.73% jump to $14.5 which is the analysts’ median price.
If we refocus on Verve Therapeutics Inc (NASDAQ:VERV), historical trading data shows that trading volumes averaged 3.51 over the past 10 days and 2.70 million over the past 3 months. The company’s latest data on shares outstanding shows there are 88.76 million shares.
The 25.54% of Verve Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 70.00% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 16.56 million on 2025-04-15, giving us a short ratio of 3.98. The data shows that as of 2025-04-15 short interest in Verve Therapeutics Inc (VERV) stood at 2207.0 of shares outstanding, with shares short rising to 15.27 million registered in 2025-03-14. Current price change has pushed the stock 0.53% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VERV stock continues to rise going into the next quarter.
